Application progress of autologous stem cell transplantation in lymphoma treatment
10.3760/cma.j.issn.1009-9921.2020.02.002
- VernacularTitle:自体干细胞移植在淋巴瘤治疗中的应用进展
- Author:
Lingyan PING
1
;
Yuqin SONG
;
Jun ZHU
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室 100142
- From:
Journal of Leukemia & Lymphoma
2020;29(2):73-78
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, due to the progress of cell-targeted therapy and the presence of a large number of new drugs, the treatment efficacy and survival of many lymphoma patients have improved. As a traditional treatment method, autologous stem cell transplantation (ASCT) still plays an important role in lymphoma treatment. ASCT can be a curable method in some clinical situations. Many clinical studies in recent years have further confirmed the role of ASCT in high-risk aggressive lymphoma and Hodgkin lymphoma. The efficacy of ASCT can be improved by combining antibodies such as brentuximab vedotin, programmed death 1, programmed death ligand 1 or chimeric antigen receptor T cell therapy, and the recurrence risk of ASCT may be decreased.
